Weihai Sinogen Pharmaceutical

Weihai Sinogen Pharmaceutical is a Chinese biopharmaceutical company specializing in the development and large-scale manufacturing of recombinant protein therapeutics. Based in Weihai, Shandong, the company is a prominent producer of cytokines, most notably Recombinant Human Interferon α2b, which is marketed under the brand name Sinogen for the treatment of viral infections and various cancers. The company also manufactures Recombinant Human Granulocyte Colony-Stimulating Factor (rhG-CSF) to manage neutropenia in patients undergoing chemotherapy. As a key subsidiary of Harbin Pharmaceutical Group (Hayao), Weihai Sinogen operates advanced GMP-certified facilities that supply the domestic Chinese market with high-quality biologics. Its business model integrates research, development, and specialized manufacturing of immune-modulating therapies.